Gynuity Health Projects

Resources

Resources by Publication Date

2017

November

WHO Model List of Essential Medicines for Treatment of Incomplete Abortion and miscarriage

Intravenous Versus Intramuscular Oxytocin for the Prevention of PPH

October

Achieving community-based postpartum follow up in eastern Uganda

Mifepristone–misoprostol for menstrual regulation in public sector facilities in Bangladesh

Study finds that obtaining abortion pills from the internet is feasible in the US

August

What Is the Most Effective, Low-Cost Method for Inducing Labor in Women With Pre-Eclampsia?

Results of a pilot study in the U.S. and Vietnam to assess the utility and acceptability of a MLPT

June

Improving Care at Delivery for Women with Preeclampsia

Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India

Postpartum Hemorrhage Prevention in Nepal: A Program Assessment

Revised And Expanded Guidance On Misoprostol-only Recommended Regimens

Profound Hyperthermia After Postpartum Rectal Misoprostol Administration

March

FAQs on the Use of Multi-level Pregnancy Tests for Medical Abortion

February

Sixteen Years of Overregulation: Time to Unburden Mifeprex

January

Dissemination and implementing a core outcome set for medical and surgical abortion

2016

December

Serial Multilevel Urine Pregnancy Testing to Assess Medical Abortion Outcome

Sexual violence-related pregnancies in eastern Democratic Republic of Congo

800μg misoprostol and mucosal and systemic immune activation or the cervicovaginal microbiome

November

Second trimester MA with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia

Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval

October

Two prophylactic medication approaches in addition to a pain control regimen for early MA

Acceptability & feasibility of 400μg buccal misoprostol after 200 mg mife for early MA in Georgia

Effects of Depot Medroxyprogesterone Acetate Injection Timing on MA Efficacy and Repeat Pregnancy

September

Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks

Home use of mifepristone and misoprostol for MA up to 10weeks of pregnancy in Kazakhstan

August

A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes

Determining early medical abortion outcomes at 3, 7 and 14 days after mifepristone

July

Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia

May

Increasing Access to Abortion With Telemedicine

Innovative research at the 2016 National Abortion Federation Annual Meeting

April

Medical abortion

February

Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the US

Effect of Immediate Compared with Delayed Insertion of Etonogestrel Implants

January

A systematic review of the relationship between blood loss and clinical signs.

Misoprostol for primary versus secondary prevention of postpartum haemorrhage

Oxytocin via Uniject versus oral misoprostol for prevention of postpartum haemorrhage

2015

December

Oxytocin in Uniject™ versus misoprostol for prevention of postpartum hemorrhage at the community

November

Contraception Program Brief

Mifepristone label laws and trends in use: recent experiences in four US states

Misoprostol for Postpartum Hemorrhage: Questions and Answers for Policy Makers

September

The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in Uganda

If we can do it for misoprostol, why not for mifepristone?

Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion

Preventing postpartum hemorrhage at the community level

Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone

Home use of urine pregnancy tests for medical abortion follow-up

A prospective, non-randomized study of home-use of mifepristone for medical abortion in the U.S.

August

Is It Safe to Provide Abortion Pills Over The Counter?

July

Fifteen years: looking back and looking forward

A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol

Secondary Prevention/Early Treatment of PPH

June

Misoprostol-induced fever and genetic polymorphisms in drug transporters

Outpatient medical abortion is safe and effective through 70 days gestation

Reaching women where they are

Off-label indications for mifepristone in gynecology and obstetrics

April

Misoprostol added to the WHO Model List of Essential Medicines for the Treatment of PPH

Early Medical Abortion without Prior Ultrasound

Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial

March

A prospective open-label study of home use of mifepristone for medical abortion in Nepal

February

Safety, efficacy and acceptability of outpatient mifepristone-misoprostol MA through 70 days

Phone follow-up with SQPT after medical abortion in Moldova and Uzbekistan

The introduction of first trimester medical abortion in Armenia

January

Self-Administration of Misoprostol for Prevention of Postpartum Hemorrhage (PPH)

2014

December

Knowledge of Abortion Laws and Services among Low-Income Women in Three United States Cities

November

Emergency Contraception: A Last Chance to Prevent Unintended Pregnancy

Mortality of induced abortion, other outpatient surgical procedures, and common activities in the US

October

Hormonal contraceptive methods and risk of HIV acquisition in women

DMPA and HIV: do we need a trial?

September

What happens when we routinely give doxycycline to medical abortion patients?

Induction of labour in preeclamptic women: a randomised trial comparing the Foley balloon catheter

August

Claims of misoprostol use based on blood sampling should be viewed with skepticism

What some women want? On-demand oral contraception

Calibrated delivery drape versus indirect gravimetric technique for the measurement of blood loss

First experience of the use of misoprostol as post-abortion care in Libreville, Gabon.

Première expérience de l’utilisation du Misoprostol comme soin après

July

Evidence versus influence in the WHO procedure for approving essential medicines

Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerb

June

Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion

May

Decentralizing postabortion care in Senegal with misoprostol for incomplete abortion

Medical abortion work in Eastern Europe/Central Asia

April

The acceptability and feasibility of remote technologies for follow-up after early medical abortion

Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria

March

Buccal misoprostol for IUFD Research Group

A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contracept

WHO Multicountry Survey on Maternal and Newborn Health Research Network

February

Treatment for primary postpartum haemorrhage

FAQ on Misoprostol Detection in Blood

Mife plus miso or miso-alone for treatment of intrauterine fetal death 12-24 weeks’ LMP

Mife plus miso or miso-alone for abortion induction in pregnancies 12-24 weeks’ LMP

January

Is One Of These Things Not Just Like The Other? Why Abortion can’t be Separated from Contraception

Acceptability and feasibility of phone follow-up after early medical abortion in Vietnam

2013

December

Reproductive Tract Cancers

Pregnancy Termination/Abortion

Pregnancy, Delivery, and Post-Natal Care

Menstruation

Infertility

Infectious Disease

Female Genital Mutilation

Family Planning

Emergency Contraceptives